Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported financial results for the third quarter ended September...

Related Keywords

Louisiana ,United States ,Japan ,New Orleans ,China ,California ,Russia ,Ukraine ,Chinese ,Japanese ,American ,Sutro Biopharma ,Arturo Molina ,Dineshv Patel ,Zealand Pharma ,Exchange Commission ,Exposition Of The American Society Hematology ,Development Rd Expenses ,Janssen Biotech Inc ,Johnson ,Protagonist Therapeutics Inc ,Chief Medical Officer ,Annual Meeting ,American Society ,Chief Executive Officer ,Subcutaneous Injectable Hepcidin Mimetic ,Polycythemia Vera ,Hepcidin Mimetic Rusfertide ,Subgroup Analysis ,Adverse Events Following Rusfertide Dosing ,Hepcidin Mimetic Provides Efficacy Benefits ,Mouse Model ,Inflation Reduction Act ,Ulcerative Colitis ,Vice President ,Oncology Scientific Innovation ,Cash Equivalents ,Marketable Securities ,Collaboration Revenue ,Janssen Phase ,Janssen Biotech ,Private Securities Litigation Reform Act ,Consolidated Statements ,Months Ended ,Protagonist Therapeutics ,Nc ,